Expert Review of Vaccines
ISSN: 1476-0584 (Print) 1744-8395 (Online) Journal homepage: http://www.tandfonline.com/loi/ierv20
Typhoid conjugate vaccines: making vaccine history in Africa James E. Meiring, Pratiksha Patel, Priyanka Patel & Melita A. Gordon To cite this article: James E. Meiring, Pratiksha Patel, Priyanka Patel & Melita A. Gordon (2018): Typhoid conjugate vaccines: making vaccine history in Africa, Expert Review of Vaccines, DOI: 10.1080/14760584.2018.1496825 To link to this article: https://doi.org/10.1080/14760584.2018.1496825
Accepted author version posted online: 04 Jul 2018. Published online: 23 Jul 2018. Submit your article to this journal
Article views: 17
View Crossmark data
Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierv20
EXPERT REVIEW OF VACCINES https://doi.org/10.1080/14760584.2018.1496825
EDITORIAL
Typhoid conjugate vaccines: making vaccine history in Africa James E. Meiring
a,b
, Pratiksha Patelb, Priyanka Patelb and Melita A. Gordonb
a
Oxford Vaccine Group, Department of Paediatrics, Oxford University, Oxford, UK; bMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi
ARTICLE HISTORY Received 15 May 2018; Accepted 2 July 2018 KEYWORDS Typhoid; Africa; conjugate vaccines; antimicrobial resistance; epidemiology; history; GAVI; WHO; Salmonella
1. Introduction The 21 February 2018 was a day in vaccine history as 4-year old Golden Kondowe became the first child in Africa to be enrolled in an individually randomized vaccine efficacy trial of a newly WHO pre-qualified typhoid conjugate vaccine (TCV) in Blantyre, Malawi. Typhoid fever, a systemic illness characterized by prolonged fever following the ingestion and subsequent invasion of the pathogen Salmonella enterica serovar Typhi (S. Typhi), has been reported from the African continent for over 100 years [1]. Known to predominate in populations with poor drinking water quality and inadequate sanitation, disease incidence has remained a public health problem for many African countries [2]. Recent and repeated introductions of multidrug resistant (MDR) S. Typhi from Asia into East and Southern Africa have resulted in widespread and prolonged epidemics in many urban centers on the continent [3,4]. With increasing urbanization applying further pressure on already fragile infrastructure, and the real threat of increasing antimicrobial resistance (AMR) to fluoroquinolones or third-generation cephalosporins emerging in Asia, the situation for Africa could yet become much worse [5]. However, the recent WHO pre-qualification of the TCV Typbar-TCV® [6] following promising vaccine efficacy results from the Oxford typhoid controlled human infection model (CHIM) [7] provides hope that there is now a vaccine which may have impact on global typhoid burden.
2. Epidemiology Data from which to estimate typhoid burden in Africa are limited to only a few population-based studies from within the continent. A systematic review including seven studies estimated a total number of 3,090,395 cases in Africa per year with 33,490 deaths [2]. Since this publication, the Typhoid Surveillance in Africa Program (TSAP), a large multisite study, performed surveillance across 10 countries, in 13 sites, with incidence estimates ranging from 0 up to 383 cases per 100,000 person-years observation [8]. What is very clear is the significant spatial and temporal heterogeneity of typhoid burden in Africa. There has been a well-documented increase
in cases throughout East and Central/Southern Africa following multiple introductions of the H58 MDR strain from the Indian subcontinent, and there have been well-described local epidemics and outbreaks with this clade [4,9–12] while different non-H58 MDR clades have been shown to circulate in West Africa [13]. The distribution of cases between urban and rural sites is currently unclear and represents a major data gap. Following the increase in case numbers witnessed after the introduction of MDR S. Typhi, there is concern over the current extensively drug-resistant (XDR) outbreak in Pakistan [5]. Within many resource-poor African countries, access to the necessary antibiotics is limited and they are more costly. The scenario of untreatable typhoid infection is foreseeable making the Strategic Advisory Group of Experts (SAGE) recommendation of vaccine introduction to countries with high AMR both timely and relevant [14]. Indeed, this may be the first vaccine where AMR is acting as a predominant motivation for introduction. Improvements in both drinking water quality and sanitation have been successful in reducing the rates of disease in many developed countries, but interventions on this scale for much of Africa would require a long timescale and large investment, underlining again the importance of vaccination for more immediate control and reduction of disease. Unlike in Asia, Salmonella enterica serovar Paratyphi (S. Paratyphi), the other major cause of enteric fever, has not been demonstrated to cause a large disease burden in Africa. Currently, there is no licensed vaccine for S. Paratyphi although some are in development.
3. Typhoid vaccines Two typhoid vaccine trials have previously been conducted in Africa. The first in Alexandria, Egypt, using the live, oral Ty21a vaccine demonstrating a statistically significant reduction in typhoid fever cases in the vaccine arm with 0 blood cultureconfirmed cases compared to the placebo arm with seven cases following 1 year of surveillance in children aged 6–7 years [15]. The second in the Transvaal region of South Africa using a Vi-capsular polysaccharide (Vi-PS) vaccine demonstrated a protective efficacy of 64% in children aged
CONTACT James E. Meiring
[email protected] Oxford Vaccine Group, Department of Paediatrics, Oxford University, Oxford, UK; MalawiLiverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi © 2018 Informa UK Limited, trading as Taylor & Francis Group
2
JAMES E. MEIRING ET AL.
5–15 years after 21 months of surveillance [16]. Similar results were replicated in field trials in Asia, and both the Vi-PS and Ty21a vaccines received WHO recommendation in 2008 for programmatic use in countries with high burden [17]. However, due to the relatively low efficacy demonstrated particularly for younger children due to the T-cell-independent nature of the polysaccharide vaccine, the scarcity of data on burden of disease, and the impending arrival of more efficacious conjugate vaccines, GAVI funding was delayed. The Tybar-TCV vaccine developed by Bharat Biotech International, Hyderabad, India, consists of 25 μg of Vi polysaccharide conjugated to a nontoxic tetanus toxoid protein carrier. Conjugation induces a T-cell-dependent response with improved immunogenic properties allowing administration in early infancy [18]. Immunogenicity data from a phase 3 study of the Tybar-TCV performed in India demonstrated consistently higher anti-Vi IgG responses than the Vi-polysaccharide control (anti-Vi IgG 1292 to 1937 EU/ml Typbar-TCV® vs. 411 EU/ml Typbar Vi). The vaccine was noted to be immunogenic in children under 2 years of age, and long-term persistence of anti-Vi has been demonstrated from 3 to 5 years postvaccination [19]. Recent data from the Oxford typhoid CHIM, where healthy volunteers received Tybar-TCV, Vi-PS, or control vaccine and then 1 month later received oral challenge with live typhoid bacteria, demonstrated a protective efficacy of 87.1% when a clinical end point of fever >38°C for >12 h followed by positive blood culture was used [7]. Both the immunogenicity and CHIM efficacy data were important in securing WHO pre-qualification. With evidence of immunogenicity and now efficacy within the constraints of CHIM, what is now required for policy makers and individual governments are field trials to demonstrate the degree of clinical impact alongside cost-effectiveness data to demonstrate the economic benefit that countries could expect to see through the introduction of this vaccine. Cost-effectiveness analyses from modeling data suggest that TCV introduction would be cost-effective, and even cost-saving in certain epidemiological contexts, with the largest impact demonstrated by combining routine vaccination with a catch-up campaign of older age groups [20].
4. Further evidence being generated Building on the recently published TSAP program, the Bill and Melinda Gates Foundation (BMGF)-funded Severe Typhoid Fever Surveillance in Africa (SETA) program is conducting further epidemiological research investigating the incidence and nature of severe typhoid disease across six different sites in Africa [21]. With joint funding from the BMGF and the Wellcome Trust, the Strategic Typhoid alliance across Africa and Asia (STRATAA) study is conducting a comprehensive program of research to further understand the burden of enteric fever with sites in Africa and Asia, aiming to improve the understanding of incidence, transmission, AMR, and diagnostics for typhoid in different epidemiological settings [22]. With $36.9 million funding from BMGF, TyVAC has brought together key partners from the University of Maryland Centre for Vaccine Development, the University of Oxford’s Oxford Vaccine Group, and PATH to accelerate the introduction of TCVs into areas of the world. In Blantyre, Malawi, building on an already
well-established typhoid surveillance system at the Malawi Liverpool Wellcome Trust Clinical Research Programme [22], an individually randomized, double-blind, controlled trial recruiting 24,000 children aged 9 months to 12 years comparing the protective efficacy of Tybar-TCV to Meningococcal A vaccine has begun. With effective engagement of local communities, ministries of health and education, and community leaders, a schoolbased vaccine campaign is under way aiming to vaccinate the total number of children in less than 6 months with a period of passive blood culture surveillance for confirmed S. Typhi bacteremia for up to 3 years. The primary outcome for the trial is to determine the efficacy of Typbar-TCV in reducing the rates of symptomatic, blood culture-confirmed S. Typhi infections among vaccinated children compared to control. There are a number of secondary outcomes related to the safety and immunogenicity of the vaccine within a subset of participants. Alongside this, there are a number of exploratory, non-etiologic outcomes measuring the impact of vaccine against things such as all fever presentation to health-care facilities, antibiotic usage, blood culture collection, and severe complications and mortality. A separate trial is being run in parallel to estimate the economic impact of typhoid on both the individual and institutional level to provide cost of illness and cost-effectiveness data.
5. GAVI, the vaccine alliance In November 2017, GAVI approved US$85 million worth of funding for the 2019–2020 window to support eligible countries to introduce TCVs [23]. Considering 36 of the 47 GAVI-eligible countries are within Africa, this presents a huge opportunity for the continent. Looking at recent introductions of new vaccines into the continent, rotavirus and pneumococcal conjugate vaccines have been introduced into 29 and 33 different GAVI-eligible African countries, respectively, often ahead of schedule and demonstrating significant impact on disease burden [24–26].
6. Conclusion With robust evidence of the high incidence of infection across many African countries, pre-qualification of a safe and efficacious vaccine demonstrated through CHIM, applicable field trials underway collecting the efficacy and economic evidence individual countries require, and the commitment of funding bodies to introduce, Golden Kondowe may prove to be the first of millions of children within Africa to receive and be protected by this vaccine, reducing the burden of typhoid, protecting against growing AMR, and improving the lives of many across the continent.
Funding The manuscript was not funded.
Declaration of interest J Meiring was funded by the Wellcome Trust Strategic Award No. 106158/ Z/14/Z. M Gordon was funded by the Strategic Typhoid Alliance across Africa and Asia funding Wellcome Trust Strategic Award No. No. 106158/ Z/14/Z and the Bill and Melinda Gates Foundation No. OPP1141321.
EXPERT REVIEW OF VACCINES
Typhoid Vaccine Acceleration Consortium Funding from Bill and Melinda Gates Foundation No OPP1151153. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
ORCID James E. Meiring
http://orcid.org/0000-0001-9183-5174
References Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers. 1. The war in South Africa. BMJ [Internet]. Br Med J Publishing Group. 1900 Jul 7 [cited 2018 Apr 18];2(2062):49–53. DOI:10.1136/ bmj.2.2062.49 2. Mogasale V, Maskery B, Ochiai RL, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literaturebased update with risk-factor adjustment. Lancet Glob Heal [Internet]. 2014 Oct [cited 2016 Jun 28];2(10):e570–e80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25304633 • Systematic review of burden of typhoid fever within low- and middle-income countries, with risk factor estimate adjustment providing data on likely burden of disease throughout Africa. 3. Wong VK, Baker S, Pickard DJ, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events. Nat Genet [Internet]. 2015 May 11 [cited 2016 Dec 7];47(6):632–639. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25961941 •• Genomic analysis describing the spread of MDR typhi from South Asia into Southern Africa and beyond. 4. Feasey NA, Gaskell K, Wong V, et al. Rapid emergence of multidrug resistant, H58-lineage Salmonella typhi in Blantyre, Malawi. PLoS Negl Trop Dis. 2015;9(4). 5. Klemm EJ, Shakoor S, Page AJ, et al. Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. MBio [Internet]. Am Soc Microbiol. 2018 Feb 20 [cited 2018 Apr 18];9(1):e00105–e18. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29463654 •• Data from Pakistan reporting on the current XDR S. Typhi outbreak with evidence of international spread. 6. Burki T. Typhoid conjugate vaccine gets WHO prequalification. Lancet Infect Dis [Internet]. Elsevier. 2018 Mar 1 [cited 2018 Mar 7];18(3):258. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 29485093 7. Jin C, Gibani MM, Moore M, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet (London, England) [Internet]. Elsevier; 2017 Sep 28 [cited 2017 Oct 11]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/28965718 •• Efficacy data for the Tybar-TCV from the Oxford controlled human infection model demonstrating a clinical efficacy of 87% for the vaccine. 8. Marks F, von Kalckreuth V, Aaby P, et al. Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob Heal [Internet]. 2017 Mar [cited 2017 Feb 27];5(3):e310–e23. Available from: http://linkin ghub.elsevier.com/retrieve/pii/S2214109X17300220
3
• Largest surveillance study of typhoid fever within Africa to date providing data on burden of disease in 13 sites across 10 countries. 9. Pitzer VE, Feasey NA, Msefula C, et al. Mathematical modeling to assess the drivers of the recent emergence of typhoid fever in Blantyre, Malawi. Clin Infect Dis [Internet]. 2015 Nov 1 [cited 2016 Nov 18];61(suppl 4):S251–S8. Available from: http://cid.oxfordjour nals.org/lookup/doi/10.1093/cid/civ710 10. Lutterloh E, Likaka A, Sejvar J, et al. Multidrug-resistant typhoid fever with neurologic findings on the Malawi-Mozambique border. Clin Infect Dis. 2012 Apr;54(8):1100–1106. United States. 11. Neil KP, Sodha SV, Lukwago L, et al. A large outbreak of typhoid fever associated with a high rate of intestinal perforation in Kasese District, Uganda, 2008–2009. Clin Infect Dis. 2012 Apr;54(8):1091– 1099. United States. 12. Kabwama SN, Bulage L, Nsubuga F, et al. A large and persistent outbreak of typhoid fever caused by consuming contaminated water and street-vended beverages: Kampala, Uganda, January– June 2015. BMC Public Health [Internet]. BioMed Central. 2017 Jan 5 [cited 2017 Aug 3];17(1):23. Available from: http://www. ncbi.nlm.nih.gov/pubmed/28056940 13. Wong VK, Holt KE, Okoro C, et al. Molecular surveillance identifies multiple transmissions of typhoid in West Africa. Ryan ET, editor. PLoS Negl Trop Dis [Internet]. 2016 Sep 22 [cited 2016 Nov 23];10 (9):e0004781. Public Library of Science. Available from: http://dx. plos.org/10.1371/journal.pntd.0004781 14. WHO | SAGE meeting of October 2017. WHO [Internet]. World Health Organization. 2017 [cited 2018 Jan 21]; Available from: http://www.who.int/immunization/sage/meetings/2017/october/ presentations_background_docs/en/ 15. Wahdan MH, Serie C, Germanier R, et al. A controlled field trial of liver oral typhoid vaccine Ty21a. Bull World Health Organ. 1980;58 (3):469–474. Switzerland. 16. Klugman KP, Gilbertson IT, Koornhof HJ, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet. 1987 Nov;2(8569):1165–1169. 17. WHO |. Weekly Epidemiological Record; 8 February 2008;83(6):49– 60. WHO 2012. 18. Kossaczka Z, Lin FY, Ho VA, et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun. United States. 1999 Nov;67(11):5806–5810. 19. Mohan VK, Varanasi V, Singh A, et al. Safety and immunogenicity of a Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis [Internet]. 2015 Aug 1 [cited 2016 Dec 8];61(3):393–402. Available from: http://www.ncbi.nlm. nih.gov/pubmed/25870324 •• Safety and immunogenicity data for the Tybar-TCV from a phase II study conducted in India on children and adults. 20. Antillón M, Bilcke J, Paltiel AD, et al. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middleincome settings. Vaccine [Internet]. Elsevier; 2017 Jun 14 [cited 2017 Oct 11];35(27):3506–3514. Available from: http://www.ncbi. nlm.nih.gov/pubmed/28527687 21. Park SE Severe typhoid fever surveillance in Africa (SETA) program: first data from the six African sites. [cited 2018 May 9]; Available from: http://www.coalitionagainsttyphoid.org/wp-content/uploads/2016/ 07/22-SETA-The-First-Data-from-the-Six-African-Sites.pdf 22. Darton TC, Meiring JE, Tonks S, et al. The STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance, serological studies and healthcare utilisation surveys. BMJ Open [Internet]. 2017 Jun 2 [cited 2017 Jul 26];7(6):e016283. Available from: http://bmjopen.bmj.com/lookup/doi/10.1136/bmjo pen-2017-016283 23. Gavi TVA Millions of children set to be protected against typhoid fever Gavi, the vaccine alliance [internet]. [cited 2018 Apr 19].
4
JAMES E. MEIRING ET AL.
Available from: https://www.gavi.org/library/news/press-releases/ 2017/millions-of-children-set-to-be-protected-against-typhoidfever/ 24. Carole Tevi-Benissan M, Moturi E, Anya B-PM, et al. Contribution of polio eradication initiative to effective new vaccine introduction in Africa, 2010–2015. Vaccine [Internet]. 2016 Oct 10 [cited 2018 Apr 19];34(43):5193–5198. Elsevier. Available from: https://www.science direct.com/science/article/pii/S0264410X16303899?via%3Dihub 25. Bar-Zeev N, Kapanda L, Tate JE, et al. Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out:
an observational and case-control study. Lancet Infect Dis [Internet]. 2015 Apr 1 [cited 2018 Apr 20];15(4):422–428. Elsevier. Available from: https://www.sciencedirect.com/science/article/pii/ S1473309914710606?via%3Dihub 26. McCollum ED, Nambiar B, Deula R, et al. Impact of the 13-valent pneumococcal conjugate vaccine on clinical and hypoxemic childhood pneumonia over three years in central Malawi: an observational study. Borrow R, editor. PLoS One [Internet]. 2017 Jan 4 [cited 2018 Apr 20];12(1):e0168209. Public Library of Science. DOI:10.1371/journal.pone.0168209
